Solid Biosciences Inc. (NASDAQ:SLDB) Insider Gabriel Brooks Sells 2,923 Shares of Stock

Solid Biosciences Inc. (NASDAQ:SLDB) insider Gabriel Brooks sold 2,923 shares of the company’s stock in a transaction on Monday, October 21st. The stock was sold at an average price of $6.50, for a total value of $18,999.50. Following the transaction, the insider now owns 10,979 shares of the company’s stock, valued at approximately $71,363.50. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Solid Biosciences Price Performance

NASDAQ SLDB opened at $5.70 on Wednesday. Solid Biosciences Inc. has a 12 month low of $1.81 and a 12 month high of $15.05. The firm has a market capitalization of $220.02 million, a PE ratio of -1.73 and a beta of 1.90. The company’s 50 day simple moving average is $7.73 and its 200 day simple moving average is $8.13.

Solid Biosciences (NASDAQ:SLDB) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.61) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.66) by $0.05. Sell-side analysts anticipate that Solid Biosciences Inc. will post -2.61 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of Solid Biosciences in a research report on Wednesday, August 14th. William Blair upgraded shares of Solid Biosciences to a “strong-buy” rating in a research report on Friday, August 30th. Barclays cut their price target on Solid Biosciences from $18.00 to $15.00 and set an “overweight” rating on the stock in a report on Wednesday, August 14th. Finally, JPMorgan Chase & Co. raised Solid Biosciences from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $10.00 to $15.00 in a report on Monday, July 15th. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Solid Biosciences presently has an average rating of “Buy” and an average target price of $15.67.

Institutional Investors Weigh In On Solid Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Dimensional Fund Advisors LP grew its stake in shares of Solid Biosciences by 8.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 70,827 shares of the company’s stock worth $402,000 after purchasing an additional 5,287 shares during the last quarter. American Century Companies Inc. grew its position in Solid Biosciences by 39.9% in the second quarter. American Century Companies Inc. now owns 34,557 shares of the company’s stock worth $196,000 after buying an additional 9,853 shares during the last quarter. Point72 DIFC Ltd bought a new position in shares of Solid Biosciences in the second quarter valued at $58,000. Ground Swell Capital LLC bought a new stake in shares of Solid Biosciences during the 2nd quarter worth $76,000. Finally, Algert Global LLC acquired a new position in shares of Solid Biosciences in the 2nd quarter worth $82,000. 81.46% of the stock is owned by institutional investors and hedge funds.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.